Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Homologous recombination proficiency in ovarian and breast cancer patients
Justin F. Creeden, Nisha S. Nanavaty, Katelyn R. Einloth, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides
Erik N. Bergstrom, Ammal Abbasi, Marcos Díaz‐Gay, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 30, pp. 3550-3560
Open Access | Times Cited: 10
Double‐strand DNA break repair: molecular mechanisms and therapeutic targets
Jinpeng Tan, Xingyao Sun, Hongling Zhao, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 21
Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
Łukasz Biegała, Arkadiusz Gajek, Agnieszka Marczak, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1038-1038
Open Access | Times Cited: 16
BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer
Tala Ismail, Safa Alzneika, Emna Riguene, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 333-333
Open Access | Times Cited: 7
DNA damage response in breast cancer and its significant role in guiding novel precise therapies
Jiayi Li, Ziqi Jia, Dong Lin, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency
Peng Yuan, Nan Ma, Binghe Xu
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2774-2792
Open Access | Times Cited: 6
Long-read sequencing of an advanced cancer cohort resolves rearrangements, unravels haplotypes, and reveals methylation landscapes
Kieran O’Neill, Erin Pleasance, Jeremy Fan, et al.
Cell Genomics (2024) Vol. 4, Iss. 11, pp. 100674-100674
Open Access | Times Cited: 6
Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management
Akiyo Yoshimura, Issei Imoto, Hiroji Iwata
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7481-7481
Open Access | Times Cited: 27
Senataxin and R-loops homeostasis: multifaced implications in carcinogenesis
Veronica Gatti, Sara De Domenico, Gerry Melino, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy
Umer Ali, Sunitha Vungarala, Venkataswarup Tiriveedhi
Genes (2024) Vol. 15, Iss. 2, pp. 162-162
Open Access | Times Cited: 5
Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
Sabine Matou‐Nasri, M Sarawatense Aldawood, Fatimah Alanazi, et al.
Diagnostics (2023) Vol. 13, Iss. 14, pp. 2390-2390
Open Access | Times Cited: 11
Discovery of 3-hydroxymethyl-azetidine derivatives as potent polymerase theta inhibitors
Shaobin Wang, Chao Wang, Jinxin Liu, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 103, pp. 117662-117662
Closed Access | Times Cited: 4
CT-based radiomics predicts HRD score and HRD status in patients with ovarian cancer
Yujiao Wu, Qianhui Zhang, Wenyan Jiang, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Causative Genes of Homologous Recombination Deficiency (HRD)-Related Breast Cancer and Specific Strategies at Present
Seigo Nakamura, Yasuyuki Kojima, Sayoko Takeuchi
Current Oncology (2025) Vol. 32, Iss. 2, pp. 90-90
Open Access
The American Joint Committee on Cancer (AJCC) Breast Cancer Staging, Eighth Edition, is more Reflective of Cancer Biology than the Seventh Edition
Jessica Young, Mariko Asaoka, Farhad Ghasemi, et al.
Annals of Surgical Oncology (2025)
Closed Access
MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability
James Ephraums, Janet Youkhana, Aparna Raina, et al.
Neoplasia (2025) Vol. 61, pp. 101138-101138
Open Access
Characterization of Immune Landscape Based on Homologous Recombination Deficiency Associated Signatures and Identification of Knockdown of ERCC6L to Promote Radiosensitivity in Breast Cancer
Jiahao Li, Gong Chen, Haiting Zhou, et al.
The Journal of Gene Medicine (2025) Vol. 27, Iss. 2
Closed Access
Molecular Management of High-Grade Serous Ovarian Carcinoma
Paula Punzón-Jiménez, Víctor Lago, Santiago Domingo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13777-13777
Open Access | Times Cited: 18
Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
Gilda Magliacane, Emanuela Brunetto, Silvia Calzavara, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 43-43
Open Access | Times Cited: 16
Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials
Roli Purwar, Rakesh Ranjan, Manjusha Pal, et al.
World Journal of Surgical Oncology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 10
Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer
Lan Zhang, Yongqi Zhen, Feng Lu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115648-115648
Closed Access | Times Cited: 9
PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer
Abdul K. Siraj, Poyil Pratheeshkumar, Divya Padmaja, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 3
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
Nadja Stiegeler, Dale W. Garsed, George Au‐Yeung, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials
Guojuan Sun, Yi Liu
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma
Zhixuan You, Meng Lv, Xuanyu He, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top